Characteristics | Albumin-adjusted calcium concentration (mg/dL) | P value | |||||||
---|---|---|---|---|---|---|---|---|---|
8.42-8.69 | 8.70-8.93 | 8.94-9.22 | 9.23-10.42 | ||||||
n | 213 | 237 | 181 | 202 | |||||
Age (year) |  | 67.9 ± 11.4 | 66.6 ± 13.3 | 68.3 ± 12.6 | 68.4 ± 12.9 | 0.188 | |||
Male, n (%) | Â | 142 (66.7) | 143 (60.3) | 99 (54.7) | 102 (50.5) | 0.006 | |||
Hypertension, n (%) | Â | 105 (49.3) | 120 (50.6) | 89 (49.2) | 115 (56.9) | 0.353 | |||
ACEI/ARB use, n (%) | Â | 101 (47.4) | 98 (41.4) | 76 (42.0) | 103 (51.0) | 0.150 | |||
Smoking, n (%) | Â | 57 (26.8) | 54 (22.8) | 37 (20.4) | 42 (20.8) | 0.402 | |||
Duration of diabetes (year) |  | 10.1 ± 8.0 | 10.4 ± 9.1 | 10.7 ± 8.1 | 10.4 ± 8.7 | 0.041 | |||
SBP (mmHg) |  | 137.1 ± 19.2 | 137.8 ± 19.6 | 135.4 ± 21.6 | 137.2 ± 18.3 | 0.672 | |||
DBP (mmHg) |  | 79.2 ± 10.0 | 79.6 ± 11.2 | 79.5 ± 12.2 | 78.8 ± 10.8 | 0.894 | |||
BMI (kg/m2) |  | 24.5 ± 3.4 | 24.5 ± 4.1 | 24.3 ± 4.0 | 24.0 ± 3.8 | 0.105 | |||
Obesity, n (%) | Â | 25 (11.7) | 37 (15.6) | 31 (17.1) | 31 (15.3) | 0.472 | |||
Laboratory | Â | Â | Â | Â | Â | Â | |||
 | FPG (mmol/L) | 7.04 ± 1.97 | 7.57 ± 2.82 | 7.88 ± 3.04 | 8.92 ± 4.16 | < 0.001 | |||
 | lg HOMA-IR | 0.53 ± 0.30 | 0.57 ± 0.32 | 0.61 ± 0.33 | 0.63 ± 0.36 | 0.011 | |||
 | HbA1c (%) | 8.12 ± 1.96 | 7.94 ± 1.74 | 8.17 ± 1.95 | 8.34 ± 2.06 | 0.181 | |||
 | Albumin (g/L) | 39.72 ± 4.42 | 38.90 ± 5.44 | 38.91 ± 4.16 | 36.85 ± 5.14 | 0.002 | |||
 | Uric acid (μmol/L) | 320.68 ± 95.21 | 336.17 ± 97.88 | 336.90 ± 98.26 | 359.72 ± 113.81 | 0.913 | |||
 | Creatinine (μmol/L) | 78.36 ± 20.31 | 83.13 ± 25.94 | 82.61 ± 24.86 | 85.24 ± 26.32 | 0.531 | |||
 | lg Alb/Cr (mg/g) | 1.60 ± 0.71 | 1.65 ± 0.72 | 1.79 ± 0.68 | 1.83 ± 0.66 | < 0.001 | |||
 | Micro-albuminuria, n (%) | 107 (50.2) | 126 (53.2) | 113 (62.4) | 130 (64.4) | 0.007 | |||
 | TG (mmol/L) | 1.79 ± 1.10 | 1.85 ± 1.17 | 1.73 ± 1.05 | 1.94 ± 1.39 | 0.329 | |||
 | TC (mmol/L) | 4.59 ± 1.12 | 4.89 ± 1.07 | 4.77 ± 1.26 | 4.98 ± 1.19 | 0.003 | |||
 | HDL-C (mmol/L) | 1.08 ± 0.31 | 1.12 ± 0.28 | 1.19 ± 0.56 | 1.06 ± 0.27 | 0.301 | |||
 | LDL-C (mmol/L) | 2.63 ± 0.82 | 2.77 ± 0.79 | 2.62 ± 0.92 | 2.88 ± 0.85 | 0.004 | |||
 | Dyslipidemia, n (%) | 114 (53.5) | 123 (51.9) | 87 (48.1) | 124 (61.4) | 0.060 | |||
 | albumin-adjusted-Calcium (mg/dL) | 8.57 ± 0.08 | 8.84 ± 0.07 | 9.10 ± 0.08 | 9.52 ± 0.26 | < 0.001 | |||
 | Phosphate (mg/dL) | 3.48 ± 0.43 | 3.54 ± 0.44 | 3.61 ± 0.47 | 3.59 ± 0.49 | 0.021 | |||
LV dimension | |||||||||
 | LVIDD (mm) | 47.56 ± 4.19 | 47.03 ± 4.82 | 47.22 ± 4.57 | 47.99 ± 4.42 | 0.142 | |||
 | LVIDS (mm) | 29.89 ± 4.20 | 30.09 ± 3.62 | 30.49 ± 4.32 | 30.89 ± 4.46 | 0.066 | |||
 | IVSD (mm) | 10.27 ± 1.45 | 10.84 ± 1.52 | 10.66 ± 1.59 | 11.13 ± 1.73 | < 0.001 | |||
 | PWTD (mm) | 9.48 ± 1.24 | 9.91 ± 1.34 | 9.93 ± 1.22 | 10.09 ± 1.45 | < 0.001 | |||
 | RWT | 0.40 ± 0.06 | 0.43 ± 0.08 | 0.42 ± 0.06 | 0.42 ± 0.07 | < 0.001 | |||
 | LVMI (g/m2) | 94.20 ± 19.02 | 101.51 ± 21.62 | 101.77 ± 22.65 | 111.21 ± 27.93 | < 0.001 | |||
 | LVEF (%) | 65.77 ± 7.45 | 64.68 ± 6.97 | 63.69 ± 8.26 | 64.87 ± 7.53 | 0.056 | |||
LV geometry | Â | Â | Â | Â | Â | Â | |||
 | Normal (%) | 54.0 | 40.9 | 35.4 | 31.2 | < 0.001 | |||
 | Concentric remodeling (%) | 23.0 | 21.5 | 27.6 | 15.3 | ||||
 | Eccentric hypertrophy (%) | 12.2 | 18.1 | 15.5 | 21.3 | ||||
 | Concentric hypertrophy (%) | 10.8 | 19.4 | 21.5 | 32.2 | ||||
LVH, (%) | Â | 23.0 | 37.6 | 37.0 | 53.5 | < 0.001 |